Page last updated: 2024-08-21

formestane and megestrol acetate

formestane has been researched along with megestrol acetate in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (75.00)18.2507
2000's1 (12.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
Frost, VJ; Helle, SI; Holly, JM; Lønning, PE; van der Stappen, JW1
Bonnefoi, H; Castiglione, M; Cavalli, F; Fey, MF; Goldhirsch, A; Hsu-Schmitz, SF; Löhnert, T; Morant, R; Thürlimann, B1
Rubens, RD1
Blijham, GH; de Jong, PC1
Bernhard, J; Bonnefoi, H; Castiglione-Gertsch, M; Cavalli, F; Fey, MF; Goldhirsch, A; Hürny, C; Morant, R; Schmitz, SF; Thürlimann, B2
Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I1

Reviews

1 review(s) available for formestane and megestrol acetate

ArticleYear
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    The Netherlands journal of medicine, 1999, Volume: 55, Issue:2

    Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles

1999

Trials

4 trial(s) available for formestane and megestrol acetate

ArticleYear
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Prospective Studies; Receptors, Estrogen; Regression Analysis; Remission Induction; Tamoxifen; Time Factors; Treatment Failure

1997
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:6

    Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Megestrol Acetate; Middle Aged; Quality of Life; Tamoxifen; Treatment Failure

1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Quality of Life; Statistics as Topic; Treatment Outcome

1999
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
    Breast cancer research and treatment, 2003, Volume: 79, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles

2003

Other Studies

3 other study(ies) available for formestane and megestrol acetate

ArticleYear
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:6

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Endopeptidases; Female; Humans; Insulin-Like Growth Factor Binding Proteins; Megestrol Acetate; Middle Aged; Radioimmunoassay; Somatomedins

1996
Aromatase inhibitors for breast cancer--further progress.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:7

    Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Megestrol Acetate

1997